Gamida Cell Ltd.
Harey Yehuda 54
212 articles about Gamida Cell Ltd.
Patient Enrollment in Phase 3 Study of NiCord® on Track for Completion in Second Half of 2019; Topline Results Expected in First Half of 2020
The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
Gamida Cell Announces Publication of Phase 1/2 Clinical Data of NiCord® in the Journal of Clinical Oncology
Gamida Cell Ltd. today announced the publication of data from the previously reported, multi-center Phase 1/2 clinical study evaluating the safety and efficacy of NiCord® as a stand-alone, hematopoietic stem cell (bone marrow) transplant in the Journal of Clinical Oncology1,2.
Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that Julian Adams, Ph.D., the company’s chief executive officer, will participate in a fireside chat at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference on Wednesday, December 12th at 1:20 p.m. ET in New York, NY.
Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that new translational data for NiCord®, an investigational cell therapy in Phase 3 clinical development for allogeneic stem cell, or bone marrow, transplant, will be presented at the American Society of Hematology (ASH) 2018 Annual Meeting,
A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.
10/31/2018October was a busy month as multiple biopharma companies made their debut as publicly traded entities and even more companies filed their intentions to go public with an initial public offering. BioSpace takes a look back at some of the key IPOs of the month.
Gamida Cell Ltd., a leading cellular and immune therapeutics company, today announced the pricing of its initial public offering of 6,250,000 ordinary shares at a public offering price of $8.00 per share for aggregate gross proceeds of $50.0 million
Six months after officially launching and one month after securing $120 million in private financing, Allogene Therapeutics is looking to score between $272 and $288 million from an initial public offering.
Gamida Cell Ltd. filed for a $69 million initial public offering for the Nasdaq exchange, according to a filing submitted last week to the U.S. Securities and Exchange Commission, Israel’s Calcalist first reported last week.
Julian Adams, Ph.D., Gamida Cell’s chief executive officer and previous chairman, will remain on the company’s board of directors.
Gamida Cell Expands its Leadership Team with the Appointment of Jaren Madden as Vice President, Investor Relations and Corporate Communications
Ms. Madden brings nearly 20 years of strategic communications experience to this new role at Gamida Cell, and will be responsible for the company’s engagement with the investment community as well as leading Gamida Cell’s media relations activities.
Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access
Gamida Cell today announced the appointments of Tzvi Palash as chief operating officer (COO) and John D. Schick as vice president, market access.
Gamida Cell Receives Orphan Drug Designation from the FDA for NiCord® as a Treatment for Hematopoietic Stem Cell Transplantation
Gamida Cell announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for NiCord as a treatment for hematopoietic stem cell transplantation (HSCT).
Gamida Cell to Present Preliminary Data from Ongoing Phase I NAM-NK Study at AACR International Meeting on Advances in Malignant Lymphoma
Gamida Cell announced that preliminary data from an ongoing phase I study from the nicotinamide-based natural killer cell expansion, or NAM-NK, program will be presented during the Inaugural AACR International Meeting on Advances in Malignant Lymphoma
Gamida Cell announced that data from the company’s NiCord program will be presented during the International Society for Cellular Therapy (ISCT) Annual Meeting, held May 2-5 in Montreal.
Gamida Cell Strengthens Leadership Team with Appointments of Josh Hamermesh as Chief Business Officer and Paul Nee as Vice President of Marketing
Mr. Hamermesh will lead the business operations and corporate development strategies for the company
Mr. Lankry brings more than a decade of senior management experience in finance at both public and private companies to his new role as CFO of Gamida Cell.
Gamida Cell Announces Initiation of a Phase I Study of NAM-NK Cells Immunotherapy Program for Non-Hodgkin Lymphoma and Multiple Myeloma
Gamida Cell today announced the initiation of a phase I study evaluating its proprietary NAM-expanded natural killer cells (NAM-NK Cells) in patients with relapsed or refractory CD20+ non-Hodgkin lymphoma (NHL) and multiple myeloma.
The study met its primary endpoint, demonstrating rapid neutrophil engraftment with manageable side effects.